Needham analyst Serge Belanger upgraded Verrica Pharmaceuticals to Buy from Hold with a $10 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRCA:
- Verrica Pharmaceuticals director buys $1.0M in common stock
- Verrica Pharma (NASDAQ:VRCA) Tanks on $125M Debt Financing Plan
- Verrica enters non-binding term sheet for up to $125M debt financing
- Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
- Verrica Parmaceuticals trading resumes